SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas ($BOIL) is surging dramatically due to extreme cold weather forecasts and polar vortex threats across the US, signaling expectations of substantial natural gas demand and potential production impacts. The community is abuzz with discussions of massive gains and short squeezes, grappling with the asset's inherent volatility as many celebrate long positions while others caution about a potential reversal. This intense debate reflects the highly weather-sensitive nature of natural gas and its leveraged ETFs.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is a key focus of market discussion amidst heightened volatility, primarily driven by concerns around geopolitical rhetoric on tariffs and the proposed acquisition of Greenland. While some traders express frustration over perceived market manipulation and "liquidity injections," others anticipate a rapid recovery, positioning for a potential bounce in tech leadership.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is experiencing significant volatility, declining sharply as natural gas prices surge amidst forecasts for an intense cold snap and potential polar vortex activity, which is driving up heating demand. This dramatic movement has fueled extensive community debate, with many viewing KOLD's steep drop as a potential "buy the dip" opportunity while others caution about the inherent risks and rapid reversals characteristic of leveraged natural gas products.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano is trending amidst a wave of strong community discussion, fueled by news of CME Group's plans for futures contracts and the approval of a significant on-chain governance proposal. While many anticipate an imminent "third wave rally" and significant gains, a vocal segment expresses skepticism, highlighting past performance and potential for further downside in the broader crypto market.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as its Q4 earnings beat was met with a cautious Q1 outlook and projections for increased content spending, creating a split in community sentiment. While many see the current dip as a significant buying opportunity, citing strong fundamentals and the potential content benefits from the pending Warner Bros. acquisition, others remain concerned about the associated debt, a pause in buybacks, and signs of maturing growth.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Mind Medicine Inc - Ordinary Shares (Sub Voting)

Mind Medicine, now rebranded as Definium Therapeutics (DFTX), is a central topic of discussion following its ticker change and recent positive Phase 2b clinical trial data. The community is actively debating the rebrand while also highlighting the significant potential of MM120 (LSD) for Generalized Anxiety Disorder after its data was published in JAMA, generating widespread media attention and bullish analyst price targets. This development positions the company as a key player in the evolving psychedelic therapeutics sector.

United States Commodity Funds LLC - United States Natural Gas Fund

United States Natural Gas Fund, LP

United States Natural Gas Fund (UNG) is experiencing significant market attention as natural gas futures surge, primarily fueled by widespread brutal cold weather forecasts and the threat of a polar vortex, which is driving up heating demand. Community chatter highlights both intense bullish sentiment anticipating a short squeeze and cautious notes regarding the commodity's historical volatility and supply dynamics. Amidst this weather-driven momentum, discussions also emphasize natural gas's long-term role in powering the rapidly expanding AI data center infrastructure.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is actively discussed amidst significant market volatility, primarily influenced by evolving geopolitical trade concerns impacting the broader tech sector. Despite recent headlines, community discussion highlights immense demand for NVIDIA's AI chips, reportedly sold out through 2027, with many investors viewing current dips as a compelling buying opportunity. This showcases an ongoing tension between macro uncertainties and NVIDIA's foundational role in the rapidly expanding AI infrastructure.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending following robust Phase 1 clinical trial results for its eczema treatment, soquelitinib, which demonstrated significant efficacy and a favorable safety profile. This promising data initially drove a notable surge, but the company's subsequent announcement of a proposed public offering has ignited community debate over potential share dilution and its implications for future trials.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group (NBIS) is trending following its selection for Israel's National AI Supercomputer project and reports of a significantly increased valuation for its ClickHouse stake, bolstering its asset base. While community discussion includes varied updates on US data center approvals and broader market volatility, many remain focused on NBIS's long-term potential in the AI infrastructure sector. Investors are actively debating the company's strategic investments and major contracts, with some viewing current dips as buying opportunities amid perceived short-term manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc...

Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN

Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the...

SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Notifies Vistagen (VTGN) Investors of the Pending Class Action Lawsuit

SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Notifies Vistagen (VTGN) Investors of the Pending Class Action Lawsuit SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Notifies Vistagen (VTGN...

VTGN Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Vistagen Therapeutics, Inc.

VTGN Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Vistagen Therapeutics, Inc. VTGN Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit...

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire...

Rosen Law Firm Urges Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and...

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. (Vistagen or the Company) (NASDAQ: VTGN) for...

Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action

Robbins LLP informs investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1...

<ul class="summary-bullets"><li>PALISADE-3 aimed to assess acute anxiety relief during public speaking challenges.</li><li>Participants received a single intranasal dose of fasedienol and were assessed during a simulated public speaking challenge.</li><li>Lucid Capital downgraded Vistagen stock to ‘Neutral’ from ‘Buy’, and slashed its price target from $19 to $1.</li></ul>Vistagen (VTGN) shares tanked 82% on Wednesday after the company announced that its PALISADE-3 Phase 3 trial for fasedienol in social anxiety disorder did not meet the primary endpoint.The study aimed to assess intranasal fasedienol for acute anxiety relief during public speaking challenges.<h2 class="st-heading-2">Trial Design And Safety</h2>The trial results showed no statistically significant difference between fasedienol and placebo in reducing anxiety, as measured by the Subjective Units of Distress Scale (SUDS). The least squares mean change from baseline was 13.6 ±1.54 for fasedienol versus 14.0 ±1.51 for placebo, a difference of 0.4.PALISADE-3 was a randomized, double-blind, placebo-controlled U.S. multi-center study. Participants received a single intranasal dose of fasedienol and were assessed during a simulated public speaking challenge.&nbsp;<blockquote>“We are disappointed by the unexpected results of this public speaking challenge trial, which are inconsistent with positive outcomes observed in Phase 2 and our PALISADE-2 Phase 3 study.”-Shawn Singh, President and CEO, Vistagen.&nbsp;</blockquote><h2 class="st-heading-2">How Did Stocktwits Users React?&nbsp;</h2>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/VTGN">Vistagen stock</a> remained in ‘bullish’ territory, and message volume changed to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img style="aspect-ratio:935/115;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_17_103119_png_73b7712123.webp" alt="VTGNs Sentiment Meter and Message Volume as of 10:00 a.m. ET on Dec. 17, 2025 | Source: Stocktwits" width="935" height="115"><figcaption>VTGNs Sentiment Meter and Message Volume as of 10:00 a.m. ET on Dec. 17, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said the drop in the stock may be exaggerated, considering the company has cash, other pipeline projects, and the treatment isn’t completely worthless.<stembedurl>https://stocktwits.com/TheTinyDevil/message/639428997</stembedurl>Another user suggested waiting for PALISADE-4 results.<stembedurl>https://stocktwits.com/bruegis283904/message/639417313</stembedurl>The company said it continues to investigate pherines as a potential new class of intranasal therapeutics targeting neurocircuitry.&nbsp;Lucid Capital downgraded Vistagen stock to ‘Neutral’ from ‘Buy’, and slashed its price target from $19 to $1, citing the Phase 3 PALISADE-3 trial failure and uncertainty about the success of the ongoing PALISADE-4.VTGN stock has declined by over 73% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/warner-bros-discovery-rejects-paramount-bid-and-stands-firm-on-netflix-deal/cLeOilMREqc">Warner Bros. Discovery Rejects Paramount Bid And Stands Firm On Netflix Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration VistaGen Therapeutics, August 8, 2023, Suqian, Jiangsu Province, China. 

Why Did Vistagen Stock Tank 82% Today?

VTGN Stock - The company’s PALISADE-3 Phase 3 trial showed no statistically significant difference between fasedienol and placebo in reducing anxiety.

Equity

The company’s PALISADE-3 Phase 3 trial showed no statistically significant difference between fasedienol and placebo in reducing anxiety.


Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product...

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Vistagen Therapeutics Inc.

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

VTGN
VistaGen Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VTGN News

VTGNVistaGen Therapeutics Inc